INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
npj Vaccines
October 2021
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
| Title | Disease Target | Product |
|---|---|---|
| Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019 |
Zika | INO-A002 |
| In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019 |
Zika | INO-A002 |
| In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018 |
Ebola | |
| Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018 |
CTLA-4 | |
| Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017 |
Prostate Cancer | |
| DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017 |
Influenza |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2022 INOVIO Pharmaceuticals. All rights reserved.
